-
Mashup Score: 6Long-acting antiretrovirals and HIV treatment adherence - 1 year(s) ago
Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV. Long-acting cabotegravir with rilpivirine ART has reduced required dosing frequency from once daily to once every month or every 2 months injections. This new era of long-acting ART, which…
Source: The Lancet HIVCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 0UK HIV transmission drops in the wake of COVID-19 - 1 year(s) ago
A big drop in UK new HIV diagnoses in 2020 had been linked to less testing due to the COVID-19 pandemic—but the fall has been sustained in 2021 despite increased testing. Tony Kirby reports.
Source: The Lancet HIVCategories: HIV/AIDS, Latest HeadlinesTweet-
A recent publication in @TheLancetHIV contributed to by our former chair @drlaurajwaters highlights progress made in reducing HIV transmission in the UK and further work that needs to be done as we move Towards Zero Full article available here 👉 https://t.co/ZaVy9ybQT0
-
-
Mashup Score: 6
For people with HIV on ART and with high CD4 cell counts who survived to 2015 or started ART after 2015, life expectancy was only a few years lower than that in the general population, irrespective of when ART was started. However, for people with low CD4 counts at the start of follow-up, life-expectancy estimates were substantially lower, emphasising the continuing importance of early diagnosis…
Source: The Lancet HIVCategories: Infectious Disease, Latest HeadlinesTweet-
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies https://t.co/0G44ie85eD Starting ART at ⬇️ CD4 counts significantly impacts life expectancy. @TheLancetHIV
-
-
Mashup Score: 36
For people with HIV on ART and with high CD4 cell counts who survived to 2015 or started ART after 2015, life expectancy was only a few years lower than that in the general population, irrespective of when ART was started. However, for people with low CD4 counts at the start of follow-up, life-expectancy estimates were substantially lower, emphasising the continuing importance of early diagnosis…
Source: The Lancet HIVCategories: Infectious Disease, Latest HeadlinesTweet-
People living with HIV who take antiretroviral medications (typically only 1 pill per day) have a near-normal life expectancy in the current era. Incredible progress. Vital to push for equitable access to HIV care globally. https://t.co/pDnVzVtvOP by A. Trickey et al. #HIV https://t.co/Ts2Da53wp6
-
-
Mashup Score: 3International Women's Day—how can I help? - 1 year(s) ago
Globally, 51% of people with HIV are women.1 But until quite recently, women with HIV were often referred to as a special population or regarded as a subgroup in research analyses. This situation is beginning to change, possibly galvanised by the eruption of community anger around the dolutegravir teratogenicity scare.2 However, the legacy of this special status has led to persistent inequities…
Source: The Lancet HIVCategories: HIV/AIDS, Latest HeadlinesTweet-
"#InternationalWomensDay—how can I help?" via @TheLancetHIV #IWD2023 #IWD #WomensDay https://t.co/qT4ddYZaGl
-
-
Mashup Score: 0Is it time to revise the notion that HIV-2 is benign? - 1 year(s) ago
HIV type 2 (HIV-2) qualifies as a neglected tropical disease by the standard definition of the concept—ie, a tropical infection that is especially common in low-income populations in developing countries. However, HIV-2 is not on the WHO portfolio of neglected tropical diseases, and it is commonly perceived as a rather benign cousin to the menace of HIV type 1 (HIV-1). Several challenges for…
Source: The Lancet HIVCategories: Infectious Disease, Latest HeadlinesTweet-
Always pleasing to see papers that we have had the honour of publishing cited in such an excellent talk by someone of the status of Kevin De Cock: Two on HIV-2 https://t.co/nngjwVhSdL https://t.co/jjECEV6ZAX And another on HIV incidence https://t.co/HcchPBaT99
-
-
Mashup Score: 0Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study - 1 year(s) ago
Despite leading to increases in integrase-inhibitor drug resistance, cabotegravir-PrEP introduction is likely to reduce AIDS deaths in addition to HIV incidence. Long-acting cabotegravir-PrEP is predicted to be cost-effective if delivered at similar cost to oral PrEP with antibody-based rapid HIV testing.
Source: The Lancet HIVCategories: Infectious Disease, Latest HeadlinesTweet-
CAB PrEP modelling paper @TheLancetHIV LA-CAB could substantially increase PrEP uptake, reduce HIV incidence & mortality at cost of increased % of adults with INSTI RAMs (from 1.7% to 13%). Programme costs similar if monitored with HIV antibody (not RNA) https://t.co/rVEVBDV6Im
-
-
Mashup Score: 20
Structural risks including discriminatory country-level policies, prosecutions, and legal barriers might contribute to higher HIV prevalence among MSM. Taken together, these data highlight the importance of decriminalisation and decreasing enforcement, alongside stigma reduction, as central to effective control for HIV.
Source: The Lancet HIVCategories: Healthcare Professionals, Latest HeadlinesTweet-
Ten years of work in 10 countries, 25 study sites, dozens of collaborators, and over 8000 participants showing that criminalizing gay men is the most significant predictor of HIV risk. There is no path to ending #HIV or #AIDS with punitive laws in place. https://t.co/HN67jOaBjI https://t.co/WwcwoNOYlD
-
-
Mashup Score: 2
Past-year physical or sexual IPV was associated with recent HIV acquisition and less frequent viral load suppression. Preventing IPV is inherently imperative but eliminating IPV could contribute to ending the HIV epidemic.
Source: The Lancet HIVCategories: Latest Headlines, NeurologyTweet-
“The effects of intimate partner violence on women’s risk of HIV acquisition and engagement in the HIV treatment and care cascade: a pooled analysis of nationally representative surveys in sub-Saharan Africa” by Salome Kuchukhidze et al. Lancet HIV https://t.co/zbATYiAcPs
-
-
Mashup Score: 0Application of artificial intelligence and machine learning for HIV prevention interventions - 1 year(s) ago
In 2019, the US Government announced its goal to end the HIV epidemic within 10 years, mirroring the initiatives set forth by UNAIDS. Public health prevention interventions are a crucial part of this ambitious goal. However, numerous challenges to this goal exist, including improving HIV awareness, increasing early HIV infection detection, ensuring rapid treatment, optimising resource…
Source: The Lancet HIVCategories: Infectious Disease, Latest HeadlinesTweet-
2022 in @TheLancetHIV covers! All artwork by Sonwabo Valashiya. Jan: Application of artificial intelligence and machine learning for HIV prevention interventions by Yang Xiang @UTHealthHouston and colleagues https://t.co/UX9yQF8N9c https://t.co/SwQLGt2plU
-
Long-acting antiretrovirals and HIV treatment adherence - think long-acting can be a game changer for those with adherence challenges but 1) we should test in viremic; 2) WHO consider endorsement worldwide https://t.co/o0rDFulBgu